News

MECHNIKOV Institute and the Chinese company Xiamen Innovax Biotech CO., LTD. (INNOVAX) signed the collaboration agreement

On November 28, 2022 the MECHNIKOV Institute and the Chinese company Xiamen Innovax Biotech CO., LTD. (INNOVAX) signed the collaboration agreement for the sanitary registration and distribution in the Republic of Nicaragua of the bivalent recombinant vaccine against the human papillomavirus (HPV) Cecolin®. The vaccine has been developed by the company
INNOVAX and has achieved the prequalification of the World Health Organization (WHO).


The human papillomavirus (HPV) is the main cause of cervical cancer, one of the most frequent female cancers worldwide. Being a very common virus, HPV can also cause other types of cancers.

Apart from the sanitary registration and distribution in the Nicaraguan territory, the collaboration between the MECHNIKOV Institute and the INNOVAX company is also about the future production of the vaccine in the facilities of the MECHNIKOV Institute.
2022 latest news